Role of Probiotics doubtful in Irritable bowel syndrome

Written By :  Niveditha Subramani
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-08-24 14:30 GMT   |   Update On 2023-08-24 14:30 GMT

Irritable bowel syndrome (IBS) is a most common gastrointestinal condition. Studies regarding the treatment of IBS with probiotics have not yielded consistent results over the past few decades, and the best probiotics is not yet hallmarked. Researchers in a recent study reveals that some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence...

Login or Register to read the full article

Irritable bowel syndrome (IBS) is a most common gastrointestinal condition. Studies regarding the treatment of IBS with probiotics have not yielded consistent results over the past few decades, and the best probiotics is not yet hallmarked.

Researchers in a recent study reveals that some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low. However, if gastroenterologists are to be able to recommend probiotics in patients with confidence, a better evidence base is needed suggested the authors. The findings of the study is published in journal Gastroentrology.

The researchers conducted a search in MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to March 2023. Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.

The key findings of the study

• Researchers identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains.

• For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains.

• For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains.

• For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains.

• The relative risk of experiencing any adverse event, in 55 trials, including over 7000 patients, was not significantly higher with probiotics.

Researchers concluded that “Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all our analyses.”

Reference: Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black et al; Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis; August 02, 2023; DOI:https://doi.org/10.1053/j.gastro.2023.07.018

Tags:    
Article Source : Gastroentrology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News